Immunic, Inc.

IMUX

US4525EP1011

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
1.24 ^USD	0.00%		+2.48%	-17.33%

Apr. 09	Transcript : Immunic, Inc. - Special Call
Mar. 21	Immunic Gets US Patent Notice of Allowance For Specific Polymorph of Vidofludimus Calcium	MT

Immunic, Inc.(NasdaqGS:IMUX) added to S&P Global BMI Index

September 20, 2021 at 12:00 am EDT

Latest news about Immunic, Inc.

Transcript : Immunic, Inc. - Special Call	Apr. 09
Immunic Gets US Patent Notice of Allowance For Specific Polymorph of Vidofludimus Calcium	Mar. 21	MT
Wedbush Adjusts Immunic's PT to $4 From $7 on Increased Sharecount From First Tranche of Private Placemebt, Keeps Outperform Rating	Feb. 23	MT
Transcript : Immunic, Inc., Q4 2023 Earnings Call, Feb 22, 2024	Feb. 22
Immunic, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Immunic Launches 3-Tranche Private Placement of Up to $240 Million; Shares Rise	Jan. 05	MT
Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected	Jan. 05	MT
Investors Await Jobs Data as US Futures Trend Lower in Friday's Premarket	Jan. 05	MT
Top Premarket Gainers	Jan. 05	MT
Immunic Files $250 Million Mixed-Securities Shelf Registration	Nov. 22	MT
Immunic Receives Notice of Allowance From US Patent Office for Dosing Regimens for Treating Multiple Sclerosis	Nov. 21	MT
Transcript : Immunic, Inc., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
Immunic, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
North American Morning Briefing : Caution Dominates Ahead of CPI Print	Nov. 14	DJ
Immunic, Inc. Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis Vidofludimus and Its Salts	Nov. 02	CI
Immunic Says Early-Stage Trial Shows 'Positive Effects' of Celiac Disease Drug Over Placebo	23-10-16	MT
Immunic, Inc. Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023	23-10-15	CI
Wedbush Adjusts Price Target on Immunic to $7 From $5, Maintains Outperform Rating	23-10-10	MT
Transcript : Immunic, Inc. - Special Call	23-10-10
Top Premarket Gainers	23-10-10	MT
North American Morning Briefing: Treasury Yields Dive as Rate-Rise Fears Ease	23-10-10	DJ
Immunic Says Phase 2 Trial Reinforces Vidofludimus Calcium's Neuroprotective Potential; Shares Soar Premarket	23-10-10	MT
Health Care Up on Deal Activity -- Health Care Roundup	23-10-09	DJ
Immunic Says Phase 2 Trial Further Reinforces Vidofludimus Calcium's Neuroprotective Potential; Shares Rise After Hours	23-10-09	MT
Immunic Reports Positive Interim Data from Phase 2 Calliper Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis	23-10-09	CI

Immunic, Inc. is a biotechnology company. The Company is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Companyâs s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase II clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease. IMU-381 is in preclinical testing, a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.24 USD

Average target price

11.5 USD

Spread / Average Target

+827.42%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
IMMUNIC, INC.	-17.33%	112M
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	104B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.42B
ARGENX SE	+1.75%	22.2B
BIONTECH SE	-16.53%	21.23B
GENMAB A/S	-8.96%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-20.09%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	13.98B
SAREPTA THERAPEUTICS, INC.	+28.85%	11.66B

Bio Therapeutic Drugs

Immunic, Inc.

Equities

IMUX

US4525EP1011

Biotechnology & Medical Research

Immunic, Inc.(NasdaqGS:IMUX) added to S&P Global BMI Index

Latest news about Immunic, Inc.

Chart Immunic, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs